Table 1.
Baseline demographics
| Ocrelizumab | Natalizumab | Fumarate | Interferon beta | p value | |
|---|---|---|---|---|---|
| n | 16 | 12 | 11 | 6 | |
| Age, mean ± SD (range), years | 52.6 ± 7.3 (38–64) | 42.9 ± 13.7 (20–59) | 48.5 ± 11.5 (27–62) | 50.2 ± 9.3 (40–65) | 0.135 |
| Female, n (%) | 12 (75.0) | 10 (83.3) | 10 (90.9) | 5 (83.3) | 0.764 |
| Racea | |||||
| White, n (%) | 16 (100) | 5 (50) | 6 (67) | 3 (50) | 0.015 |
| Black, n (%) | 0 (0) | 5 (50) | 3 (33) | 3 (50) | 0.015 |
| Body mass index, mean ± SD | 32.8 ± 9.9 | 27.3 ± 6.2 | 27.3 ± 4.1 | 27.0 ± 6.4 | 0.112 |
| Time since MS onset, mean ± SD (range), years | 16.3 ± 7.3 (4.5–29.4) | 14.3 ± 12.3 (2.4–39.2) | 15.8 ± 9.5 (4.1–33.2) | 10.6 ± 4.6 (5.2–17.2) | 0.603 |
| Time since MS diagnosis, mean ± SD (range), years | 10.5 ± 8.1 (2.2–24.4) | 10.8 ± 9.5 (1.4–26.1) | 12.8 ± 9.2 (3.1–30.2) | 10.1 ± 5.0 (5.2–17.2) | 0.721 |
| EDSS score, mean ± SD (range)a | 2.8 ± 1.6 (1.5–6.0) | 1.9 ± 1.2 (1.0–4.5) | 2.1 ± 0.5 (1.5–3.0) | 2.5 ± 1.1 (1.5–4.0) | 0.445 |
| Duration of DMT exposure, mean ± SD (range), months | 27.3 ± 8.7 (16–42) | 51.2 ± 50.8 (10–185) | 49.8 ± 35.1 (12–95) | 108 ± 54.1 (61–206) | 0.0007b |
| DMT washout, mean ± SD (range), days | 129.8 ± 34.1 (83–192) | N/A | N/A | N/A | N/A |
Statistical analysis was one-way analysis of variance with multiple comparisons against all groups when overall p < 0.05, or chi-square (categorical variables) without multiple comparisons
DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, MS multiple sclerosis, N/A not available
aData not available for all participants
bParticipants receiving interferon beta therapy had a longer duration of DMT exposure